Tech Company Financing Transactions

Arch Oncology Funding Round

Lightchain, 3x5 Special Opportunity Partners and RiverVest Venture Partners participated in a $50 million Series B funding round for Arch Oncology. The round was announced on 3/26/2019.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series B
Proceeds Purpose
The Company plans to use the proceeds from this financing to advance its anti-CD47 antibody AO-176's ongoing Phase 1 clinical trial in select solid tumors, as well as its pipeline.

Company Information

Company Status
Private & Independent
Mailing Address
2000 Sierra Point Pkwy. 700
Brisbane, CA 94005
Email Address
Arch Oncology is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
Arch Oncology LinkedIn Company Profile
Social Media
Arch Oncology Company Twitter Account
Company News
Arch Oncology News
Arch Oncology on Facebook
Arch Oncology on YouTube

Management Team

Email & Social
Chief Executive Officer
Laurence Blumberg
  Laurence Blumberg LinkedIn Profile  Laurence Blumberg Twitter Account  Laurence Blumberg News  Laurence Blumberg on Facebook
Chief Medical Officer
Jackie Walling
  Jackie Walling LinkedIn Profile  Jackie Walling Twitter Account  Jackie Walling News  Jackie Walling on Facebook
Chief Operating Officer
Ronald Krasnow
  Ronald Krasnow LinkedIn Profile  Ronald Krasnow Twitter Account  Ronald Krasnow News  Ronald Krasnow on Facebook
Chief Scientific Officer
Daniel Pereira
  Daniel Pereira LinkedIn Profile  Daniel Pereira Twitter Account  Daniel Pereira News  Daniel Pereira on Facebook
Vice President
Vicki Sung
  Vicki Sung LinkedIn Profile  Vicki Sung Twitter Account  Vicki Sung News  Vicki Sung on Facebook
VP - Finance
Galit Yaakobovitz
  Galit Yaakobovitz LinkedIn Profile  Galit Yaakobovitz Twitter Account  Galit Yaakobovitz News  Galit Yaakobovitz on Facebook
VP - Operations
Kevin Romanko
  Kevin Romanko LinkedIn Profile  Kevin Romanko Twitter Account  Kevin Romanko News  Kevin Romanko on Facebook
VP - R & D
Arun Kashyap
  Arun Kashyap LinkedIn Profile  Arun Kashyap Twitter Account  Arun Kashyap News  Arun Kashyap on Facebook
VP - Regulatory Affairs
Michele DeVries
  Michele DeVries LinkedIn Profile  Michele DeVries Twitter Account  Michele DeVries News  Michele DeVries on Facebook



Browse more venture capital transactions:

Prev: 3/26/2019: Ouster venture capital transaction
Next: 3/26/2019: Mursion venture capital transaction


Share this article


About Our Venture Capital Transactions Database

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary